TOX/See multi-Drugscreen Panel 8-test (AMP1000/COC/MOR300/THC/BZO/MET1000/MTD/BAR)

Products	TOX/See multi-Drugscreen Panel 8-test (AMP1000/COC/MOR300/THC/BZO/MET1000/MTD/BAR)
Company	Bio-Rad Laboratories
Item	TOX/See multi-Drugscreen Panel 8-test (AMP1000/COC/MOR300/THC/BZO/MET1000/MTD/BAR)
Features	ComprehensiveTests for as many as 9 drugs per cassette EfficientOne-step test protocol FastResults in as few as 3 minutes
Description	TOX/See™ is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine. The TOX/See device can detect up to nine of the most commonly abused drugs in 3 to 8 minutes and requires only a few drops of urine. Each TOX/See cassette is individually packaged to maximize convenience and ease of use. TOX/See features integrated test controls, easy-to-read results, and an 18-month shelf life at room temperature. The completed test card can be photocopied and archived for health and legal records. The straightforward test protocol is designed for use by all levels of staff in hospitals, emergency departments, correctional facilities, juvenile facilities, police departments, workplaces, and recovery and rehabilitation programs.
Info	Bio-Rad Laboratories Customer Service: 1-800-2-BIORAD Web site: http://www.bio-rad.com

TAG: TOX See multi Drugscreen Panel test AMP1000 COC MOR300 THC BZO MET1000 MTD BAR

...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...

Medicine Products:

Allergen, Food, Cherry Allergen, Food, Chicken Allergen, Food, Casein Allergen, Food, Blueberry

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...ST, the peer-reviewed journal of the American Coll...dietary intake of certain nutrients increases the ... especially in teens who smoke. Teenagers who for...e a harder time catching their breath. Furthermore...

...2007, issue of Neurology, the medical journal of t...ly Parkinsons disease report a higher than anticip...leepiness, and swelling. By identifying risk fact...isions, allow for early intervention and possibly ...

...mpaign to boost fruit and vegetable intake among y... Professor Janet Cade and colleagues of Leeds Un...nd Vegetable Scheme (SFVS), installed in 2004, on ... the north of England. A specially devised measure...

...therapy (HRT) should not be prescribed to older wo...ent chronic conditions such as heart disease . But...hort term treatment for younger women in early men...oms and improve quality of life. In 2002, the Wom...

Other Medicine News:Health News:Apple a Day Keeps Asthma Away 2 Health News:Apple a Day Keeps Asthma Away 3 Health News:Early Parkinsons Show Hallucination,sleepiness 2 Health News:Britains Free Fruit -And -Vegetable -Scheme Falls Flat 2 Health News:Study Confirms No HRT Benefit for Older Women 2 Health News:Study Confirms No HRT Benefit for Older Women 3

Apple a Day Keeps Asthma Away Early Parkinsons Show Hallucination,sleepiness Britains Free Fruit -And -Vegetable -Scheme Falls Flat Study Confirms No HRT Benefit for Older Women

(Date:8/19/2008).../- VION,PHARMACEUTICALS, IN...,entered into an agreement with the Dutch-Belgian ...he "HOVON") to conduct a clinical trial of,laromus...mission-induction,therapy in patients aged 18-65 w...a (AML) and high-risk myelodysplasia (MDS)., Alan...

(Date:8/18/2008)...for increased life expectancy for people with,Down...wire/ -- In the world of Down,syndrome, ,Mr. C, is...racked for the past 16 years, at seventy, ,Mr. C, ...a person with Down syndrome, currently in the,late...Further, ,Mr. C, does,not exhibit clinical symptom...

(Date:8/18/2008)...Newswire-FirstCall/ -- Micromet, Inc.,(Nasdaq: MI..., proprietary,antibodies for the treatment of canc...t a webcast and conference call this morning, Mond...:00 p.m. Central European,Time) to discuss the bli...SCIENCE on August 15, 2008., To access the webcas...

(Date:8/14/2008)...- Pharmasset, Inc.,(Nasdaq:...committed to,discovering, developing and commercia...rted unaudited financial results for the third fis...ed a net loss attributable to,common stockholders ... the,quarter ended June 30, 2008, as compared to a...

Breaking Medicine Technology:Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 2 Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 3 Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2 Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3 Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2 Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3 Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8 Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9 Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 1 Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 2 Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 3 Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 4 Weizmann Institute scientists develop a new approach to treating autoimmune disease 20822 1 Weizmann Institute scientists develop a new approach to treating autoimmune disease 20822 2 Lung Cancer Alliance Hails Announcement of New Erbitux 28R 29 Data 2284 1 Lung Cancer Alliance Hails Announcement of New Erbitux 28R 29 Data 2284 2 Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 20816 1 Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 20816 2 Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 20816 3 Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 20816 4 Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 20816 5 Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 20816 6

[0] Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy [0] Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community [0] Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE [0] Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

..., UK, June 11, 2007-ReGen is pleased to announce t...n on Colostrinin, its,nutraceutical product which ...healthy cognitive function, was presented today at...ne in Surfers,Paradise, Queensland, Australia by D... , The conference, which is being attended by key ...

...AKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTE...MYGN) (<a target=,"_blank" href="http://www.myriad...esented a mathematical comparison of a,"Staggered ...l,design with a "Natural History Staggered Start" ...on Prevention Conference held,June 9 - 12, 2007, i...

Other Medicine Technology:Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia 2 Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2 Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3 Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4 Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5

Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification